BRPI0809441A2 - Formulação farmacêuticas de moléculas ghrh - Google Patents

Formulação farmacêuticas de moléculas ghrh

Info

Publication number
BRPI0809441A2
BRPI0809441A2 BRPI0809441-1A BRPI0809441A BRPI0809441A2 BR PI0809441 A2 BRPI0809441 A2 BR PI0809441A2 BR PI0809441 A BRPI0809441 A BR PI0809441A BR PI0809441 A2 BRPI0809441 A2 BR PI0809441A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
ghrh molecules
ghrh
molecules
formulations
Prior art date
Application number
BRPI0809441-1A
Other languages
English (en)
Inventor
Helen Loughrey
Byeong Chang
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of BRPI0809441A2 publication Critical patent/BRPI0809441A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0809441-1A 2007-04-04 2008-04-04 Formulação farmacêuticas de moléculas ghrh BRPI0809441A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90998507P 2007-04-04 2007-04-04
PCT/CA2008/000637 WO2008122118A1 (en) 2007-04-04 2008-04-04 Pharmaceutical formulations of ghrh molecules

Publications (1)

Publication Number Publication Date
BRPI0809441A2 true BRPI0809441A2 (pt) 2015-06-23

Family

ID=39827484

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809441-1A BRPI0809441A2 (pt) 2007-04-04 2008-04-04 Formulação farmacêuticas de moléculas ghrh

Country Status (13)

Country Link
US (1) US20080249017A1 (pt)
EP (1) EP2142207A4 (pt)
JP (1) JP2010523501A (pt)
KR (1) KR20090130044A (pt)
CN (1) CN101678083A (pt)
AU (1) AU2008235215A1 (pt)
BR (1) BRPI0809441A2 (pt)
CA (1) CA2680329A1 (pt)
IL (1) IL200810A0 (pt)
MX (1) MX2009010675A (pt)
RU (1) RU2009140731A (pt)
WO (1) WO2008122118A1 (pt)
ZA (1) ZA200906179B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4778053B2 (ja) * 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
JP5582983B2 (ja) * 2010-11-24 2014-09-03 楠本化成株式会社 水系沈降防止剤
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
JP2016027003A (ja) * 2012-11-20 2016-02-18 大蔵製薬株式会社 長期間安定なオランザピンの水性医薬製剤
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
CN113646327A (zh) 2019-03-29 2021-11-12 综合医院公司 用于治疗肝脏疾病的ghrh或其类似物
US20230270865A1 (en) * 2020-07-05 2023-08-31 Theratechnologies Inc. Low-dose pharmaceutical compositions of ghrh analogs and uses thereof
WO2024133908A1 (en) * 2022-12-23 2024-06-27 Syna Therapeutics, S.L. Stable pharmaceutical compositions comprising romiplostim

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137872A (en) * 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
EP0880969A1 (en) * 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Pharmaceutical compositions of peptides having low solubility in physiological medium
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
WO2000006124A2 (en) * 1998-07-30 2000-02-10 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
AU9558901A (en) * 2000-10-05 2002-04-15 Ares Trading Sa Regioselective liquid phase pegylation
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
CA2472956A1 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US7662393B2 (en) * 2004-04-07 2010-02-16 Ares Trading S.A. Liquid growth hormone formulation and method of use
EP1812048A4 (en) * 2004-10-20 2012-01-18 Theratechnologies Inc GH SECRETAGOGA AND ITS USE
CA2593112A1 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion

Also Published As

Publication number Publication date
EP2142207A4 (en) 2013-01-16
RU2009140731A (ru) 2011-05-10
CA2680329A1 (en) 2008-10-16
JP2010523501A (ja) 2010-07-15
AU2008235215A2 (en) 2011-02-24
EP2142207A1 (en) 2010-01-13
CN101678083A (zh) 2010-03-24
AU2008235215A1 (en) 2008-10-16
MX2009010675A (es) 2009-10-23
IL200810A0 (en) 2010-05-17
WO2008122118A1 (en) 2008-10-16
ZA200906179B (en) 2010-05-26
KR20090130044A (ko) 2009-12-17
US20080249017A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
LTC2140867I2 (lt) Farmacinė kompozicija
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0809441A2 (pt) Formulação farmacêuticas de moléculas ghrh
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0721651A2 (pt) Composição farmacêutica
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
EP2191826A4 (en) PHARMACEUTICAL COMPOSITION
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0921654A2 (pt) formulação farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
PT2209464E (pt) Composição farmacêutica antimalárica
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0820198A2 (pt) composições farmacêuticas
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0817053A2 (pt) Formulações farmacêuticas de orlistat
BRPI0912171A2 (pt) composição farmacêutica
BRPI0921301A2 (pt) composição farmacêutica
BRPI0912656A2 (pt) formulação farmacêutica sólida
DK2271321T3 (da) Farmaceutisk sammensætning 271
EP2116241A4 (en) PHARMACEUTICAL COMPOSITION
BRPI0823402A2 (pt) Formulações farmacêuticas de olmesartan
BRPI0815597A2 (pt) Formulações de emulsões com derivado de pirazolona
EP2327406A4 (en) STABILIZED PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.